Table 1.
Participant and Clinical Blood Characteristics
| Placebo | Nitrite | |||
|---|---|---|---|---|
| Subject Characteristics | Baseline | End-Intervention | Baseline | End-Intervention |
| Age, yr | 68±1 | — | 67±1 | — |
| Males/females, n | 12/11, 23 | — | 13/13, 26 | — |
| SBP, mmHg | 130±3 | 130±2 | 126±3 | 129±3 |
| DBP, mmHg | 75±2 | 75±2 | 74±2 | 75±2 |
| Body mass, kg | 73.8±2.6 | 74.4±2.4 | 74.4±2.6 | 74.1±2.6 |
| Body mass index, kg/m2 | 26.0±0.7 | 26.0±0.7 | 25.5±0.7 | 25.5±0.7 |
| Waist circumference, cm | 86±2 | 86±2 | 84±2 | 87±3 |
| Waist:hip ratio, U | 0.86±0.02 | 0.85±0.02 | 0.84±0.02 | 0.84±0.02 |
| Total Cholesterol, mg/dl | 175±7 | 177±7 | 173±6 | 174±6 |
| HDL Cholesterol, mg/dl | 52±3 | 51±3 | 55±3 | 57±3 |
| LDL Cholesterol, mg/dl | 110±6 | 106±6 | 102±6 | 100±6 |
| Triglycerides, mg/dl | 87±8 | 98±8 | 82±7 | 85±8 |
| Glucose, mg/dl | 82±4 | 83±3 | 88±7 | 88±7 |
| C-reactive protein, mg/l | 1.00±0.31 | 1.15±0.36 | 0.94±0.14 | 1.16±0.25 |
| Oxidized LDL, U/l | 74±4 | 75±5 | 65±5 | 66±4 |
| Norepinephrine, pg/ml | 369±20 | 363±32 | 396±23 | 392±25 |
Data are mean±SEM; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; placebo n=22, nitrite n=25 for all blood values.